To review recent advances in achalasia diagnostics and therapeutics.
INTRODUCTION

High-resolution manometry (HRM) [1,2
& ] and the development of the Chicago Classification [3 & ] have substantially revised the classification of esophageal motility disorders (EMD). Nowhere is this more evident than in our concept of achalasia, now differentiated into three subtypes and a fourth entity, esophagogastric junction (EGJ) outflow obstruction. These four entities are distinguished not by differences in EGJ function, but by the associated contractility pattern of the distal esophagus, which ranges from absent contractility to intact peristalsis. Hence, to keep pace with this evolution, achalasia treatment options need to be evaluated in the context of this disease spectrum.
Coincident with the widespread adoption of the Chicago Classification into clinical practice came a major therapeutic advance in the management of EMD, peroral endoscopic myotomy (POEM) [4] . The POEM procedure allows for performing a myotomy of the lower esophageal sphincter (LES) through a mucosotomy in the proximal esophagus rather than through laparoscopy, thereby reducing the morbidity of the procedure. Furthermore, the POEM procedure allows for creation of an extended myotomy, potentially encompassing the entire smooth muscle esophagus. Together, the developments of HRM and POEM have fostered an increasing emphasis on targeting therapy to specific regions of esophageal dysfunction as assessed by physiologic testing.
The Chicago Classification is an analysis scheme for HRM studies comprising ten 5-ml swallows performed in a supine or reclined position. The three fundamental metrics utilized in the Chicago Classification are the integrated relaxation pressure (IRP), the distal contractile integral (DCI), and the distal latency. Using an algorithmic approach, these measurements are applied to identify EMD.
The adequacy of deglutitive LES relaxation, key to the recognition of achalasia, is measured by the IRP, defined as the mean pressure during the 4 s of maximal deglutitive relaxation in the 10-s window beginning at upper esophageal sphincter relaxation. The IRP is expressed as a median value of the 10 test swallows with 15 mmHg being the upper limit of normal. However, as with any metric, an IRP more than 15 mmHg is neither 100% sensitive nor 100% specific for clinically relevant EGJ outflow obstruction. When initially applied to a series of 400 patients and 73 controls, including 62 patients with achalasia, an IRP value more than 15 mmHg was found to be 98% sensitive and 96% specific for detecting achalasia [5, 6] .
The metrics employed to characterize the deglutitive contraction in the distal esophagus are the DCI and the distal latency. The DCI integrates the length, vigor, and persistence of the distal esophageal contraction spanning from the transition zone to the EGJ, expressed as mmHg s cm [7] . The DCI is used to define hypercontractile swallows (DCI > 8000 mmHg s cm), weak swallows (DCI < 450 mmHg s cm), and failed peristalsis (DCI < 100 mmHg s cm). The other major abnormality of peristalsis is of premature contractions, defined by the distal latency. Premature contractions imply inhibitory neuronal dysfunction in the distal esophagus and are the defining characteristic of distal esophageal spasm and type III achalasia [8] . The distal latency is measured from upper sphincter relaxation to the contractile deceleration point, the inflection point in the wave front velocity just proximal to the EGJ [9, 10] . A distal latency value of less than 4.5 s defines a premature contraction.
Achalasia subtypes
A diagnosis of achalasia stipulates both impaired deglutitive EGJ relaxation and absent peristalsis [11] . However, absent peristalsis is not synonymous with absent pressurization or contractility. In fact, both esophageal pressurization and nonperistaltic contractility are quite common in achalasia. A seminal observation with HRM was that absent peristalsis accompanying impaired EGJ relaxation (achalasia) can occur with three different patterns of esophageal contractility: type I, with negligible pressurization within the esophagus; type II, with panesophageal pressurization wherein nonlumenoccluding contractions cause uniform pressurization spanning from the upper sphincter to the LES; or type III, with premature (spastic) contractions [12 & ]. In multiple reported HRM series from major centers around the world, type II achalasia is the most common subtype.
Achalasia syndromes other than types I, II, and III achalasia
There is no biomarker of achalasia and, although we recognize that the underlying disorder is of a myenteric plexopathy [13] , the diagnosis is not established by neuropathology. Rather, achalasia is usually diagnosed using HRM to demonstrate that dysphagia, regurgitation, and/or chest pain is occurring as a result absent peristalsis and esophageal outflow obstruction that cannot be attributed to a stricture, tumor, vascular structure, implanted device, or infiltrating process [11] . Consequently, there are two fundamental limitations of the
KEY POINTS
The cardinal finding of achalasia, impaired EGJ relaxation, can occur with a wide spectrum of contractility in the adjacent distal esophagus ranging from absent contractility (type I achalasia) to spasm (type III achalasia) or even normal peristalsis (EGJ outflow obstruction).
The well established durable treatments for achalasia, pneumatic dilation, and laparoscopic Heller myotomy, are both 80-90% effective when done by experienced practitioners.
POEM is a new endoscopic technique for performing a myotomy of the LES and a calibrated length of adjacent esophagus, potentially the entire smooth muscle segment.
Each achalasia syndrome has unique treatment considerations; type II achalasia responds well to all therapies, whereas type III responds best to POEM.
Emerging data support the concept that optimal management of achalasia is phenotype-specific, guided by high-resolution manometry and, in some instance, functional luminal imaging probe studies.
Chicago classification with respect to diagnosing achalasia: the IRP can be less than 15 mmHg in achalasia; and there can be instances with preserved peristalsis. Furthermore, the disease evolves over a variable timespan and when there is a gradual transition from normal function to absent peristalsis and EGJ outflow obstruction there will be intermediate time points in the natural history of achalasia when these abnormalities may not achieve the requisite diagnostic thresholds.
The stipulation that the IRP must be more than 15 mmHg to have achalasia is not always true, particularly in type I disease. This is partly because, in the absence of esophageal pressurization, especially with advanced disease, some achalasics have a very low LES pressure. In fact, Lin et al. [14] proposed reducing the IRP cutoff for defining type I achalasia to 10 mmHg based on a classification and regression tree model showing that value to better discriminate between type I achalasia and the diagnosis of absent contractility. However, not even that suffices as evident in a recent publication reporting achalasics with extremely low IRP values (3 and 5 mmHg) in which impaired sphincter function was demonstrable using functional luminal imaging probe (FLIP) technology and stasis on the barium esophagram [15] . In the end, the fact is that no metric or technology has perfect sensitivity and specificity for defining relevant sphincter dysfunction and one has to weigh the entire dataset. There are instances in which measurement of the distensibility index with FLIP using a threshold of 2.8 mm 2 /mmHg is diagnostic [16] , instances in which minimal bolus flow time on a high-resolution impedance manometry study is diagnostic [17, 18] , instances when a timed barium esophagram is most demonstrative, instances in which a rapid drink challenge will elicit esophageal pressurization [19, 20] , and, of course, many instances in which an IRP more than 15 mmHg on HRM will suffice.
Fragments of peristalsis are often seen in followup HRM studies after achalasia is treated by relieving the EGJ outflow obstruction with myotomy. Roman et al. [21] reported that more than half of 30 achalasia patients studied before and after myotomy exhibited instances or either intact peristaltic contractions or remnants of distal peristalsis in their posttreatment HRM study. This likely occurs both because of variability in the pattern and intensity of distal esophageal myenteric plexus degeneration among patients and because weak peristalsis is undetectable by HRM in the setting of esophageal outflow obstruction. Hence, it is more accurate to think of posttreatment peristalsis as being 'unmasked' as opposed to 'recovered'. Reappearance of peristalsis after myotomy supports the concept of progressive stages in achalasia pathogenesis. Such progression was also suggested in a recent study showing greater ganglion cell loss in type I achalasia compared with type II achalasia, supporting the notion that type II is an earlier stage of the disease [22] . Within this construct, recovery of peristalsis after myotomy might indicate an inflamed, but surviving, distal esophageal myenteric plexus, whereas lack of recovery might indicate progression to aganglionosis. Along the same line, FLIP detected nonoccluding or occluding contractions in all of 10 type III achalasia patients, in two-thirds of the 26 type II achalasia patients tested, and in one-third of the 15 type I achalasia patients tested [23 & ]. In addition to the three subtypes of achalasia, the Chicago Classification recognizes EGJ outflow obstruction as another potential achalasia phenotype. With this entity, the IRP is more than 15 mmHg, but there is sufficient evidence of peristalsis such that the 'absent peristalsis' criterion for achalasia is not met. Even with its initial description, EGJ outflow obstruction was recognized to be a heterogeneous group, with only some such patients benefitting from achalasia treatments [24] . Consequently, EGJ outflow obstruction always requires more intense clinical evaluation (e.g., endoscopic ultrasound, FLIP, computerized tomography, etc.) to clarify its cause. The spectrum of potential causes include incompletely expressed or early achalasia, esophageal wall stiffness from an infiltrative disease or cancer, eosinophilic esophagitis, vascular obstruction, sliding or paraesophageal hiatal hernia, abdominal obesity, or the effects of opiates [25 & ]. Similar manometric findings can also be observed in patients with dysphagia after antireflux or bariatric surgery [26, 27, 28] , sometimes making it very difficult to establish cause and effect. The natural history and heterogeneity of EGJ outflow obstruction was studied in two recent series reporting that many of these patients were minimally symptomatic or asymptomatic, that in 20-40% of cases the 'disorder' resolved spontaneously, and that only 12-40% of them end up being treated as achalasia [29, 30] . Table 1 summarizes the spectrum and characteristics of potential achalasia syndromes.
PHENOTYPE-DIRECTED TREATMENT
No current treatment halts or reverses the immunologically driven plexopathy ultimately driving the progression of idiopathic achalasia [13] . Rather, treatments aim to alleviate the hallmark abnormality of the disease, esophageal outflow obstruction. Relieving outflow obstruction reduces strain on the distal esophagus and halts the progressive esophageal dilatation that drives the long-term morbidity of the disease. However, although all achalasia phenotypes share the common element of EGJ outflow obstruction, the associated pattern of esophageal contractility varies from absent contractility at one extreme to spastic contractions at the other and one of the original observations with the description of achalasia phenotypes was that treatment success varied with phenotype [12 & ]. Treatment outcomes were best in type II achalasia and likely worst in type III achalasia. Subsequent reports of patients treated either by myotomy, pneumatic dilation, or in a randomized controlled trial comparing pneumatic dilation with myotomy have confirmed these observations, especially with respect to excellent treatment outcomes in type II achalasia patients which ranged from 90 to 100% [31] [32] [33] . Going forward, it is time to compare therapies within disease subtypes, be that types I-III achalasia or the achalasia syndromes detailed in Table 1 . Each entity has unique treatment considerations and each likely has a unique optimal management strategy [34] . Beyond deglutitive sphincter dysfunction, relevant features to consider are the location and extent of obstructive contractility of the distal esophagus, the severity of esophageal dilatation and sigmoid deformation, the presence of hiatus hernia, presence of a significant epiphrenic diverticulum, and for some of the achalasia syndromes, mechanical esophageal outflow obstruction.
Pharmacological treatments for achalasia
Although conceptually appealing, there are minimal supportive data for the use of current drugs to treat achalasia by reducing LES pressure. The most studied drugs are nitrates [35] , calcium channel Apart from the achalasia subtypes, these syndromes are not specific for achalasia and may have distinct pathophysiology, but instances occur in which they are optimally managed as if they were achalasia. CART, classification and regression tree; CT, computed tomography; DCI, distal contractile integral; DES, distal esophageal spasm; DL, distal latency; EGJ, esophagogastric junction; FLIP, functional luminal imaging probe; IRP, integrated relaxation pressure; MRS, multiple repetitive swallows.
Advances in the understanding of esophageal motility disorders Kahrilas and Pandolfino blockers [35] , botulinum toxin [36] [37] [38] [39] , and, more recently, 5 0 -phosphodiesterase inhibitors [40] . However, these series are of brief duration, uncontrolled, small, and predate the concept of achalasia subtyping. Although smooth muscle relaxants may provide some symptomatic benefit, they are not durable therapies, they are often associated with intolerable side effects, and they do not halt the progression of esophageal dilatation and food retention. In the case of botulinum toxin injection into the LES, about two-thirds of achalasia patients report an improvement in dysphagia, but most relapse within a year and repeat treatments have diminished effectiveness. Nonetheless, these treatments can be useful in patients who are not fit for more durable therapies because of severe comorbidity. They can also be useful in situations of uncertainty regarding the diagnosis.
Durable achalasia treatments
Until recently, the only durable treatment options for achalasia were pneumatic dilation or laparoscopic Heller myotomy (LHM). Pneumatic dilation is done with a 30, 35, or 40-mm cylindrical balloon positioned across the LES fluoroscopically and inflated using a handheld manometer. Currently, the most widely used dilator in the United States of America is the Rigiflex noncompliant polyethylene balloon with radio-opaque markers on the shaft within the balloon (Boston Scientific, Boston, Massachusetts, USA). A recent variation on this was the introduction of a 30-mm hydraulic dilator used in conjunction with FLIP technology and not requiring concomitant fluoroscopy (Crospon, Galway, Ireland) [41] . The standard surgical alternative to pneumatic dilation is LHM, in which the circular muscle layer of the LES is surgically divided. Most surgeons advocate that the myotomy be anterior and about 7 cm in overall length, 2 cm onto the gastric cardia, and 5 cm onto the tubular esophagus. Because of the propensity for that to cause reflux, LHM is usually combined with a partial fundoplication. An extensive literature has compared LHM with pneumatic dilation [42 & ], culminating in a multicenter European randomized controlled trial comparing the two, concluding that both were about 90% effective without a significant difference between them [43, 44] . However, that trial and for that matter, all preceding trials did not consider achalasia subtypes in their design or in their assessment of treatment efficacy. Indeed, retrospectively analyzed, the European achalasia trial found the efficacy of pneumatic dilation for treating type II achalasia to be 100% [45] . Considering that the cost of pneumatic dilation is substantially less than LHM and that the risk of perforation between techniques is comparable (about 1% in expert hands) [46] , this argues for pneumatic dilation as the preferred initial treatment for type II achalasia.
The widespread adoption of the POEM procedure has been a major advance in achalasia therapeutics. The POEM procedure involves making a mucosal incision in the mid-esophagus and creating a submucosal tunnel to the gastric cardia using a standard endoscope and electrocautery [4] . A circular muscle layer myotomy is then achieved from within the submucosal tunnel, beginning at the gastric cardia and progressing proximally across the LES. Therein lies a unique attribute of POEM; the myotomy can be made longer if desired, potentially involving the entire length of smooth muscle esophagus. This is especially relevant with type III achalasia, noted to have less robust outcomes with therapies limited to the LES. Supportive of that hypothesis, a recent metaanalysis of uncontrolled POEM series reported a weighted pooled response rate of 92% (confidence interval 84-96%) in type III achalasia with the length of myotomy averaging 17.2 cm [47 && ]. If it is advantageous to extend the length of myotomy in some cases, might it not also be advantageous to limit its extent in others? To date, this is an unexplored avenue. However, two problems associated with long-term outcomes of Heller myotomy are postprocedure reflux and the formation of a pseudodiverticulum with associated bolus stasis in the esophageal segment included in the myotomy. Conceptually, both of these problems would be minimized by limiting the extent of the myotomy to the LES in types I and II achalasia, diseases in which there is no associated obstructive physiology in the distal esophagus. Intraoperatively, this could be gauged by HRM, or better, FLIP. Table 2 details the preferred therapeutic interventions for the achalasia syndromes based on physiological considerations, or, in a few cases, supportive data. The suggestions assume that all options are available and affordable, which in reality is rarely the case.
CONCLUSION
It is now recognized that the cardinal feature of achalasia, impaired LES relaxation can occur in several disease phenotypes: without peristalsis, with premature (spastic) distal esophageal contractions, with panesophageal pressurization, or with peristalsis. Furthermore, physiological testing with HRM, and sometimes FLIP, reveals a number of syndromes not meeting Chicago Classification criteria for achalasia that also benefit from therapies formerly reserved for achalasia. With HRM and the Chicago Classification, we have come to conceptualize achalasia syndromes as involving the LES with or without obstructive physiology of the distal smooth muscle esophagus. This is now particularly relevant with the development of a minimally invasive technique for performing a calibrated myotomy of the esophageal circular muscle, the POEM procedure. Hence, a major implication of this is a shift in management strategy toward rendering treatment in a phenotype-specific manner: for example, POEM calibrated to patient-specific physiology as defined by HRM for spastic achalasia, pneumatic dilation for disorders limited to abnormal LES function, especially type II achalasia, and a surgical myotomy limited to the LES for more advanced disease with esophageal dilatation, sigmoid deformation, or significant epiphrenic diverticulum.
